Vivek Subbiah and Jame Abraham
Jun 5, 2025, 14:25
Vivek Subbiah and Jame Abraham are Honored to Be Part of Editorial Board Members of The ASCO Post
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn by Jame Abraham, Chairman and Professor of the Department of Hematology and Medical Oncology at the Cleveland Clinic , adding:
“Such a great honor to be a part of the editorial board of American Society of Clinical Oncology (ASCO) ASCO POST -#1 oncology newspaper on the world with incredible line up of editors.
Thanks to Jame Abraham, M.D. FACP et al for spearheading this publication and disseminating the latest and greatest advances in oncology.”
Quoting Jame Abraham‘s post:
“It is an honor to be part of this amazing group of Editorial Board members of The ASCO Post American Society of Clinical Oncology (ASCO) – The #1 Oncology News Paper in the world, Top 3 Most read Oncology Publication along with JCO and NEJM and recognized globally as the most trusted voice in Oncology ASCO25.
Thank you Cara Glynn and Dr. Jim Armitage for your leadership! With many faces including Vivek Subbiah, MD Komal Jhaveri!”
Read OncoDaily’s Special Articles about ASCO 2025:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
Highlights from ASCO 2025 Day 3
Highlights from ASCO 2025 Day 4
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 5, 2025, 12:10